Seres plans Q1 2027 FDA submission for SER-155 study to prevent immune checkpoint inhibitor-induced colitis

Seres Therapeutics reported Q3 2026 financial results and announced plans to submit a new study design for SER-155 to the FDA in Q1 2027, which aims to prevent immune checkpoint inhibitor-related enterocolitis and keep patients on life-saving cancer therapies. This news highlights the company's expansion into a broader therapeutic opportunity with strong market relevance.